Ovarian Cancer

Combination treatment is even more effective in women with ovarian cancer with BRCA mutations or homologous recombination deficiency (HRD)-positive tumors. Read More ›

Are patient-reported outcomes (PROs) similar in the placebo and the niraparib groups, suggesting that over the course of treatment niraparib does not adversely affect patients’ quality of life? Results of the PRIMA/ENGOT-OV26/GOG-3012 trial begin to elucidate the answer to this question. Read More ›

The combination of lenvatinib + pembrolizumab exhibited a manageable safety profile and encouraging efficacy in patients with heavily pretreated ovarian cancer, as well as those with a previous history of treatment failure. Read More ›

The phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 study is exploring the use of an antimitotic therapy tumor treating (TT) fields plus weekly paclitaxel in patients with platinum-resistant ovarian cancer. Read More ›

In this study, researchers explored whether there is a potential synergistic effect of olaparib when combined with pegylated liposomal doxorubicin, highlighting a potential means to improve tolerability. Read More ›

When utilized as maintenance therapy after frontline treatment of ovarian cancer in patients with BRCAwt tumors, niraparib improved progression-free survival (PFS), even in the most difficult-to-treat patients. Read More ›

Results from a previous study indicated that treatment with the combination would lead to improvement in progression-free survival (PFS) compared with treatment with olaparib alone. Read More ›

This real-world study based primarily on community-based practice data showed that a key predictor of time to next treatment and mortality in patients with advanced ovarian cancer was visible residual disease. Read More ›

Patient-reported outcomes from the phase 3 PRIMA clinical trial showed no detrimental effect of niraparib on quality-of-life measures compared with placebo in patients with newly diagnosed ovarian cancer. Read More ›

Information on clinical aspects of COVID-19 and social and financial support services for the cancer community are abundant. Read More ›

Page 3 of 10


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: